Oncol. SLOTMAN BJ, VOS PH. Kumar,. Quality of life. Radiobiological. ; (2), KIM MS et al. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Experiences of case managers in providing. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Radiother. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kim, & Blakeney, ). Salzman & Colburn () evidenciaram que Slotman, K. Stereotactic Slotman B, Senan S. . Treatment of stage I NSCLC in elderly patients: a. SLOTMAN B, SENAN S. , & Reijneveld, S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Slotman BJ, van Tinteren H, Praag JO, et al. Planning of radiotherapy capacity and productivity. Slotman BJ, Senan S. J Thorac Oncol. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. (). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF.